Background {#Sec1}
==========

The relationship between affective disorders and eating disorders (EDs) has been well documented \[[@CR1]\], but much of the research focuses exclusively on major depressive disorder (MDD) and EDs. Eating disorders, having high co-morbid rates of psychiatric and physical disorders, have been conceptualized as having features overlapping with bipolar spectrum disorders \[[@CR2], [@CR3]\], more specifically between binge-eating related disorder and bipolar II disorder \[[@CR4]--[@CR6]\]. Studies reveal that lifetime prevalence of bipolar disorders in the ED population ranges from 0% to 34.8% in community or outpatient samples \[[@CR7], [@CR8]\], and 36% to 64% among inpatients \[[@CR9], [@CR10]\]. A few papers using diagnostic questionnaire or symptom scale have found a rate of 19% bipolar II in individuals with EDs and higher hypomania scores in individuals with binge-eating disorder (BED) than subthreshold BED \[[@CR11], [@CR12]\]. Several studies have investigated the correlates of EDs in patients with bipolar disorders \[[@CR13]--[@CR16]\], far fewer have examined the effects of bipolar disorder on patients with EDs \[[@CR6], [@CR8]\]. No studies have examined the discriminative effects of bipolar I and bipolar II disorders from MDD in patients with EDs. Recent studies adopting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition(DSM-5)'s \[[@CR17]\] broadened criteria of EDs have further substantiated their relationship \[[@CR6], [@CR18]\].

Individuals were classified as having lifetime bipolar I disorder if they had ever had a manic episode, defined as a period of seven days or longer with elevated mood, and three other mania symptoms, or with irritable mood plus four other mania symptoms, with the mood disturbance resulting in marked impairment, or hospitalization. Individuals were classified as having lifetime bipolar II disorder if they had had both major depressive episodes (MDEs) and a hypomanic episode, defined by a period of four days or longer with symptom criteria similar to mania, and with an unequivocal change in function, but without a manic episode \[[@CR19]\]. In a few other studies, concerns regarding diagnosing individuals with major depression who have a history or concomitant hypomania/mania were addressed (bipolar depression) \[[@CR20]--[@CR22]\]. Bipolar disorders are highly prevalent in clinical samples of depressed patients, with bipolar I disorder being diagnosed in 18 − 47.1% of cases, and bipolar II disorder in 7.7 − 45% \[[@CR23], [@CR24]\]. Compared with individuals with only major depression (unipolar depression), those with major depression and subthreshold mania/hypomania were found to have significantly higher rates of panic disorder, alcohol use disorders, and behavioral problems \[[@CR25], [@CR26]\]. Individuals with bipolar II disorder had even higher rates of anxiety disorders and behavioral problems than those with major depression and subthreshold mania/hypomania \[[@CR26]\].

Bipolar II disorder is defined as a milder form of bipolar disorder with regard to hypomanic symptom intensity \[[@CR17]\]. However, compared to individuals with bipolar I disorder, individuals with bipolar II disorder may have greater chronicity of illness and spend more time in the depressive phase of their illness \[[@CR27], [@CR28]\]. Some researchers have found patterns of comorbidity \[[@CR15], [@CR29]\], suicide attempts \[[@CR14], [@CR30]\], and functional impairments \[[@CR31]\] in bipolar II disorder that are equivalent to those in bipolar I disorder, but others report higher rates of psychiatric comorbidity \[[@CR30], [@CR32]\] and suicide attempts \[[@CR32]\] in bipolar II compared to bipolar I disorder. Variability in psychiatric comorbidity and functional impairments in bipolar disorders could be related to clinical heterogeneity in sample composition and index illness phase \[[@CR15], [@CR28]\].

The evidence of efficacy of drug treatments for EDs has been mostly weak or moderate \[[@CR33]\]. Fluoxetine (a selective serotonin reuptake inhibitor) remains to be the only drug approved for bulimia nervosa (BN) until Lisdexamphetamine dimesylate was approved for BED by the US Food and Drug Administration in 2015 \[[@CR34]\]. Close monitoring for emergence of hypomanic/manic symptoms is suggested when antidepressant monotherapy is utilized in the treatment of individuals with bipolar depression \[[@CR35]\]. Differentiating bipolar I and bipolar II disorders from MDD in ED patients with clinical presentations of major depression is therefore critical for pharmacological treatment.

Based on the above reviews, we hypothesized that depressed ED patients with comorbid bipolar I and bipolar II disorders had differential features from patients with comorbid MDD and those with comorbid bipolar I and II disorders were under-treated with drugs other than antidepressants. This study aimed to examine the associated features between co-occurring bipolar and unipolar disorders in depressed ED patients. We stratify bipolar disorders into bipolar I and bipolar II considering they may have different associated features from unipolar depression. Moreover, we examined the differences of prescription drugs between the three groups of depressed ED patients in clinical practice.

Methods {#Sec2}
=======

Participants and procedures {#Sec3}
---------------------------

Participants were selected from a group of ED patients (*n* = 288) who were enrolled upon their first visit to the general psychiatric clinics at a teaching hospital via a two-phase method between August 2010 and July 2014 \[[@CR6]\]. The written informed consent was obtained from the patients before enrollment. Individuals with active psychotic symptoms, mental sub-normality, organic mental conditions, and severe medical illnesses were excluded. All study participants were ED patients with current MDE, and were diagnosed by the ED module of the Structured Clinical Interview for DSM-IV-TR Axis I disorders Patient version (SCID-I/P) \[[@CR36]\] and Mini International Neuropsychiatric Interview (MINI) . They also underwent face-to-face interviews, assessing comorbid psychiatric diagnoses, history of self-injury behaviors or suicide attempts, and functional impairment. Diagnostic raters were one psychiatrist and two highly trained research assistants with degrees in psychology, who were monitored throughout the study to minimize rater drift. Participants underwent intelligence testing, and completed several questionnaires concerning eating pathology, affect lability, and impulsivity. The drugs prescribed at this index visit were recorded. The Institutional Review Board of National Taiwan University Hospital approved this study.

Measures {#Sec4}
--------

### SCID-I/P {#Sec5}

An ED diagnosis in the last three months and further in the past was established using the SCID-I/P, and adapted to meet the criteria of the DSM-5. Female patients were not required to meet the criteria of amenorrhea for anorexia nervosa (AN). The minimum frequency and duration of binge-eating/purging was once per week for three months for BN and BED \[[@CR17]\]. Participants who reported extreme weight or shape concerns, less frequent yet regular binge-eating symptoms, or binge-eating without feelings of distress, and those who did not meet other criteria for the previous disorders, were diagnosed with ED, not otherwise specified (EDNOS).

### MINI {#Sec6}

The MINI is a short, diagnostic interview for the DSM-IV and ICD-10 psychiatric disorders \[[@CR37]\]. It is divided into modules, including diagnoses of major depression, bipolar disorders, anxiety disorders, and alcohol/substance use disorders. The first 40 participant interviews were audiotaped. The κ coefficients of inter-rater reliability for all diagnoses fell between .60 (social phobia) and 1.00 (major depressive episode), except that for substance use disorder (.47). We used the MINI to assess comorbid Axis I psychiatric disorders.

### Assessment of functional impairment and suicide risks {#Sec7}

The 87-item Structured Interview for Anorexic and Bulimic Disorders, Expert-Assessment (SIAB-EX) covers a wide range of symptoms frequently seen in EDs --- body image disturbances, bulimic symptoms, social integration problems, problems associated with sexuality, depression, compulsion, and anxiety \[[@CR38]\]. Each item was rated for present status (the last three months) and for maximum pathology in previous years (lifetime). Responses were rated on a severity scale, ranging from 0 for "symptom not present" to 4 for "symptom very much/very severely present". Following an independent, professional translation of the Chinese version of the SIAB-EX, all items were reviewed by two psychiatrists. The assessment of functional impairment was adopted from item 53, "was your work performance objectively impaired at work or in your household?" Suicide risks were rated by item 69, "did you ever attempt to commit suicide?", and item 70, "did you ever hurt yourself intentionally?" Severity of suicidal acts and auto-aggressive behaviors was rated according to the number of attempts or seriousness of physical injury. Inter-rater reliability (κ coefficient) for present and lifetime severity of item 53 was .76 and .74, respectively, and ranged from .53 − .78 for items 69 and 70 \[[@CR39]\].

### Intelligence quotient and working memory assessments {#Sec8}

In this study, we used the short form of Wechsler Adult Intelligence Scale---Third Edition (WAIS--III) to assess the intelligence quotient in the groups. It comprises four subtests (Similarities, Matrix Reasoning, Arithmetic, and Digit Symbol substitution) and has been demonstrated to exceed other subtest combinations with respect to validity, content representation, and time saving \[[@CR40]\]. This short form AIS-III has been used in several studies on patients with neuropsychiatric disorders \[[@CR41]--[@CR43]\]. Scores of working memory were summed by Arithmetic and Digit Span, and were converted to the estimated percentile rank according to the Taiwanese norm \[[@CR44]\].

### Bulimic Investigatory Test Edinburgh (BITE) {#Sec9}

This self-reported measure includes the Symptom Scale (30 items) and the Severity Scale (6 items). The Chinese BITE has good internal consistency (Cronbach's α = .78 and .52, respectively) and test-retest reliability (intra-class correlation reliability of .86 and .88, respectively) for the two scales \[[@CR45]\].

### Body Shape Questionnaire (BSQ) {#Sec10}

The BSQ was initially developed as a 34-item questionnaire for assessing feelings about body shape, and the behavioral and emotional consequences of such feelings. The BSQ-8 used in this study, which has 8 items derived from the Chinese BSQ-34 \[[@CR46]\] has good internal consistency (Cronbach's alpha, α = .88).

### Affect Lability Scale (ALS) {#Sec11}

This study adopted an 18-item short form (ALS-18) that was established by selecting items from the original 54-item ALS using exploratory factor analysis with eigenvalues greater than 1 \[[@CR47]\]. The original ALS assesses people's endorsements regarding the tendency of their mood to shift between what they consider normal, to the affective domains of anger, depression, elation, and anxiety, as well as their tendency to oscillate between depression and elation, and between depression and anxiety \[[@CR48]\]. The reliability test showed excellent internal consistency for the Chinese version of the ALS-18 (Cronbach's α = .93) and item-total correlations ranged from .37 to .76.

### Beck Depression Inventory (BDI) {#Sec12}

The BDI is a 21-item measure examining depressive symptom severity over the last week. Each question has at least four response options of differing intensities. A value ranging 0--3 is assigned to each answer and the total score determines depression severity. The Chinese version of the BDI has shown good reliability and construct validity \[[@CR49]\]. and showed good internal consistency in this study (Cronbach's α = .91).

### Barratt Impulsiveness Scale (BIS) {#Sec13}

This is a 30-item self-report questionnaire measuring trait impulsivity \[[@CR50]\]. The Chinese version of BIS-11 (BIS-11-CH) is modified from the original BIS by removing five items (item 15, 21, 23, 27, and 29) with poor item-total correlations (less than .1) \[[@CR51]\]. The remaining 25 items of the BIS-11-CH had a Cronbach's α of .83, and an intact factorial structure of inability to plan (factor 1), lack of perseverance and self-control (factor 2), and propensity toward novelty-seeking and acting without thinking (factor 3) \[[@CR51]\].

Statistical analysis {#Sec14}
--------------------

Clinical and demographic characteristics of groups with MDD (ED-MDD), MDE with lifetime hypomanic episodes (ED-BP II), and MDE with lifetime manic episodes (ED-BP I) were compared. Descriptive statistics were computed to determine means and standard deviations of all continuous variables and frequency distributions for categorical variables. The differences of demographic data between groups were compared using ANOVA and Chi-square tests for continuous variables and categorical variables, respectively. With apparent differences in the distribution of gender and ED subtypes in different comorbid groups, multivariate analyses were therefore applied. Continuous variables between groups were compared using generalized linear regression with adjustments of age, gender, and ED subtype for pair-wise comparisons. Multivariate logistic regression with adjustments of age, gender, and ED subtype was employed to estimate adjusted odds ratios (AORs) with 95% confidence intervals (CIs) between groups. Since there were four subtypes in ED patients, three dummy variables were involved in the regression model. All tests were two-tailed, and *p* \< .05 was considered significant. All statistical analyses were performed using SAS, version 9.4 (Cary, North Carolina, USA).

Results {#Sec15}
=======

Demographics and clinical characteristics {#Sec16}
-----------------------------------------

Among the ED patients, 227 were diagnosed to have a current MDE. Patients who had current MDE had a later age of onset of ED compared to those who did not have (20.1 ± 6.3 vs. 18.1 ± 4.3). There were no differences of age, gender, and educational levels between the two groups. Table [1](#Tab1){ref-type="table"} shows the comparison of demographics and distribution of ED subtypes between ED-MDD (58.6%), ED-BP II (24.2%), and ED-BP I (17.2%). No statistically significant differences in age, age at ED onset, and age at depression onset, were observed between groups. Patients with ED-BP I had the lowest educational level among all. The diagnostic distribution of AN, BN, BED, and EDNOS was 41 (18.1%), 101 (44.5%), 58 (25.6%), and 27 (11.9%), respectively. ED-BP I and ED-BP II comprised of higher percentages of BN and BED patients. There were statistically significant differences of sex distribution, age, age of onset of disordered eating, and BMI among ED subtypes (Additional file [1](#MOESM1){ref-type="media"}: Table S1.1). There was less female predominance in BED group compared to AN and BN groups. Age differences only existed between BED and BN patients that patients with BED were significantly older and had a later age of onset of eating problems than patients with BN. Patients with BED were the heaviest among all for both current and previous body weight. No statistically significant difference in educational level was observed among ED subgroups. However, other EDs had significantly higher risks of association with generalized anxiety disorder, social phobia, panic disorders, agoraphobia and alcohol use disorder than AN but showed comparable risks of association with most psychiatric disorders between themselves (Additional file [1](#MOESM1){ref-type="media"}: Table S1.2).Table 1Comparison of demographics and clinical variables for eating disorder patients during major depressive episodesVariablesEating disorders with MDD (*n* = 133)Eating disorders with bipolar II disorder (*n* = 55)Eating disorders with bipolar I disorder (*n* = 39)*P*-valueGender, female (N, %)124 (93.2)46 (83.6)31 (79.5)**0.0254**Age (years)27.3 ± 7.428.2 ± 7.228.4 ± 8.80.6184Age at onset of disordered eating (years)20.3 ± 6.319.2 ± 4.420.4 ± 8.10.5211Age at onset of depression (years)22.8 ± 6.922.2 ± 6.721.4 ± 8.00.6032Education (years)14.4 ± 2.315.0 ± 2.413.0 ± 2.7**0.0005**Eating disorder subtypes (N, %)**0.0465** Anorexia Nervosa32 (24.1)4 (7.3)5 (12.8) Bulimia Nervosa60 (45.1)25 (45.5)16 (41.0) Binge eating Disorders25 (18.8)19 (34.6)14 (35.9) Eating disorders NOS16 (12.0)7 (12.7)4 (10.3)Values in bold type indicated statistically significant*MDD* major depressive disorderValues indicate N (%) or Mean ± SD

Severity of psychopathology and psychiatric comorbidity {#Sec17}
-------------------------------------------------------

Information concerning clinical correlates of the ED with different affective disorders adjusting with sex, age, and ED subtypes is presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Patients with ED-BP I had the lowest intelligence quotient and working memory score among all. Compared to the ED-MDD group, those with ED-BP I/BP II had statistically significantly severe degrees of mood lability and impulsiveness, higher current body weight and binge-eating/purging severity. Moreover, patients with ED-BP I/BP II also had a significantly higher rate of comorbidity with alcohol use disorders than ED-MDD patients. Patients with ED-BP I also had a two-fold higher co-occurrence rate of panic disorder than patients with ED-MDD. In comparison to ED-MDD and ED-BP II patients, patients with ED-BP I had more severe depression, mood lability and a greater rate of severe role impairments. The proportion of patients with ED-BP II who had attempted suicide (29%) fell between that of the bipolar I and MDD groups (36% and 17%, respectively). Only the difference between the latter two groups was statistically significant. Considering AN had distinct features of psychiatric co-morbidities from other EDs, we re-analyzed the data after excluding patients with AN. Significant differences of affective lability and current body weight between ED-MDD and ED-BP II group no longer existed and there were no significant difference of percentage of suicidal acts between groups (Additional file [2](#MOESM2){ref-type="media"}: Table S2.1 − 2.4). We also provide Additional file [3](#MOESM3){ref-type="media"}: Table S3.1 − 3.3 to show the comparison of psychiatric co-morbidity in different ED subtype patients with three groups of affective disorders. Of note, small sample size in some co-morbidity categories may cause difficulties or instability in estimation of statistical significance.Table 2Comparison of psychological assessments and BMI among depressed eating disorder patients with or without lifetime hypomania/mania episodesVariablesEating disorders with MDDEating disorders with bipolar II disorderEating disorders with bipolar I disorder2 vs. 13 vs. 13 vs. 2(1)(2)(3)(*n* = 133)(*n* = 55)(*n* = 39)Mean ± SDMean ± SDMean ± SD*P*-value^†^*P*-value^†^*P*-value^†^Intelligence quotient101.2 ± 13.7100.9 ± 12.793.0 ± 14.60.6897**0.00850.0070**Working memory54.9 ± 26.554.6 ± 29.236.4 ± 27.70.8742**0.00030.0026**Bulimic Investigatory Test Edinburgh29.7 ± 11.631.8 ± 9.130.4 ± 11.70.06950.33150.4221 Symptom subscale20.4 ± 6.421.3 ± 5.419.4 ± 6.30.22380.53350.0760 Severity subscale9.3 ± 6.610.5 ± 5.110.9 ± 7.30.0612**0.0334**0.7174Body Shape Questionnaire-84.6 ± 1.24.9 ± 1.14.4 ± 1.30.08700.5152**0.0465**Beck Depression Inventory26.2 ± 10.626.8 ± 8.831.7 ± 9.50.9275**0.00790.0125**Affective Lability Scale48.3 ± 8.751.6 ± 7.956.7 ± 8.6**0.0410\<0.00010.0039**Barrett Impulsiveness Scale58.5 ± 6.061.6 ± 6.962.4 ± 6.9**0.00180.0006**0.5505BMI, current (kg/m^2^)20.3 ± 4.823.5 ± 5.523.6 ± 6.2**0.04880.0430**0.8204BMI, maximal (kg/m^2^)23.8 ± 5.126.8 ± 6.425.7 ± 5.4**0.0243**0.47360.3549BMI, minimal (kg/m^2^)17.0 ± 3.218.7 ± 2.918.5 ± 3.80.21870.34130.8838Values in bold type indicated statistically significant*MDD* major depressive disorder, *BMI* Body mass index^†^adjusted for age, gender, and eating disorder subtypes Table 3Comparison of lifetime psychiatric diagnoses among depressed eating disorder patients with or without lifetime hypomania/mania episodeVariablesEating disorders with MDDEating disorders with bipolar II disorderEating disorders with bipolar I disorder2 vs. 13 vs. 13 vs. 2(1)(2)(3)(*n* = 133)(*n* = 55)(*n* = 39)N (%)N (%)N (%)AOR (95% CI)AOR (95% CI)AOR (95% CI)Comorbid diagnosis Generalized anxiety disorder50 (37.6)27 (49.1)20 (51.3)1.31 (0.68, 2.54)1.50 (0.71, 3.17)1.17 (0.49, 2.79) Social phobia46 (34.6)23 (41.8)18 (46.2)1.29 (0.65, 2.55)1.63 (0.76, 3.50)1.21 (0.52, 2.82) Panic disorder16 (12.0)14 (25.5)12 (30.8)2.02 (0.89, 4.60)**2.73 (1.12, 6.69)**1.47 (0.56, 3.80) Agoraphobia27 (20.3)13 (23.6)15 (38.5)0.97 (0.44, 2.11)2.14(0.95, 4.83)2.25 (0.87, 5.83) Obsessive compulsive disorder38 (28.6)19 (34.6)17 (43.6)1.23 (0.61, 2.47)1.80 (0.84, 3.85)1.52 (0.64, 3.60) Post-traumatic stress disorder15 (11.3)22 (20.0)5 (12.8)1.79 (0.74, 4.33)1.13 (0.37, 3.44)0.59 (0.18, 1.89) Alcohol abuse/dependence5 (3.8)12 (21.8)12 (30.8)**7.68 (2.41, 24.44)14.55 (4.37, 48.41)**2.05 (0.74, 5.70) Drug abuse/dependence23 (17.3)10 (18.2)10 (25.6)1.15 (0.49, 2.69)1.67 (0.69, 4.06)1.48 (0.53, 4.09)Functional impairment^b^0.87 (0.45, 1.68)^a^**4.46 (1.80, 11.04)** ^a^**5.11 (1.91, 13.72)** ^a^ Severe and very severe67 (50.4)26 (47.3)32 (82.1) Marked45 (33.8)18 (32.7)7 (18.0) None and mild21 (15.8)11 (20.0)0Suicide acts^c^23 (17.3)16 (29.1)14 (35.9)1.72 (0.80, 3.70)**2.52 (1.10, 5.77)**1.39 (0.57, 3.40)Auto-aggressive behaviors^d^41 (30.8)15 (27.3)18 (46.2)0.81 (0.39, 1.67)1.92 (0.89, 4.11)2.18 (0.89, 5.37)AOR: odd ratio adjusted for age, gender, and eating disorder subtypesValues in bold type indicated statistically significant*MDD* major depressive disorderImpairments and suicide were assessed using the Structured Interview on Anorexic and Bulimic Disorder, Expert-Assessment (SIAB-EX)^a^Patients with severe and very severe impairments compared with all others^b^: rated by the Item 53 'Was your work performance objectively impaired at work or in your household ?". Severity of impairment is rated from 0 (=no) to 4 (=very severe)^c^: rated by the item 69 'Did you ever attempt to commit suicide?'^d^: rated by the Item 70 'Did you ever hurt yourself intentionally?'. Severity of suicidal acts and auto-aggressive behaviors is rated from 0 (= symptom not present) to 4 (= symptom very much/very severely present) according to the number of attempts or seriousness of physical injury; here suicide acts indicated the severity more than one serious attempt or many minor attempts and auto-aggressive behaviors indicated the severity more than marked degree Table 4Comparison of pharmacotherapy among depressed eating disorder patients with or without lifetime hypomania/mania episode at enrollmentVariablesEating disorders with MDDEating disorders with bipolar II disorderEating disorders with bipolar I disorder2 vs. 13 vs. 13 vs. 2(1)(2)(3)(*n* = 133)(*n* = 55)(*n* = 39)N (%)N (%)N (%)AOR (95% CI)AOR (95% CI)AOR (95% CI)Antidepressant monotherapy61 (48.0)31 (56.4)10 (27.0)1.23 (0.62, 2.42)**0.35 (0.15, 0.83)0.28 (0.11, 0.72)**mood stabilizer monotherapy01 (1.8)0NANANAAtypical antipsychotic monotherapy32 (25.2)6 (10.9)9 (24.3)0.41 (0.15, 1.09)1.04 (0.41, 2.61)2.65 (0.82, 8.59)Antidepressant plus mood stabilizers1 (0.8)01 (2.7)NANANAAntidepressant plus antipsychotic17 (13.4)10 (18.2)9 (24.3)1.44 (0.56, 3.47)2.09 (0.81, 5.37)1.36 (0.46, 4.03)Antidepressant plus mood stabilizers and antipsychotics1 (0.8)1 (1.8)1 (2.7)2.26 (0.13, 39.12)4.00 (0.23, 68.78)1.78 (0.10, 30.80)Any antidepressant80 (63.0)42 (76.4)21 (56.8)1.70 (0.78, 3.72)0.70 (0.31, 1.60)**0.38 (0.15, 0.99)**Any mood stabilizer5 (3.9)3 (5.5)6 (16.2)1.01 (0.25, 4.88)**3.95 (1.06, 14.71)**3.96 (0.90, 17.44)Any atypical antipsychotic51 (40.2)17 (30.9)21 (56.8)0.72 (0.36, 1.47)2.13 (0.97, 4.65)**2.92 (1.18, 7.20)***MDD* major depressive disorderData mission for 6 and 2 persons in eating disorders with MDD and eating disorders with bipolar I disorder, respectivelyAOR: odd ratio adjusted for age, gender, and eating disorder subtypesValues in bold type indicated statistically significant

Pharmacotherapy among different groups {#Sec18}
--------------------------------------

Antidepressants were the most frequently prescribed medication (63.0%), either as monotherapy (44.9%) or concomitantly with other drugs, for ED patients with a current MDE (Table [4](#Tab4){ref-type="table"}). The percentage of patients prescribed antidepressant monotherapy in ED-BP I and ED-BP II was statistically significantly different from ED-MDD groups. Although ED-BP I patients were significantly less likely than those in the ED-MDD (AOR = 0.35, 95% CI = 0.15 − 0.83, *p* = .017) and ED-BP II (AOR = 0.28, 95% CI = 0.11 − 0.72, *p* = .008) groups to be on antidepressant monotherapy, a great rate of ED-BP I individuals taking antidepressant monotherapy (27%) was exposed to the risk of mood switch during the course of treatment. The second most commonly prescribed pharmacotherapy was atypical antipsychotic monotherapy (20.7%), followed by combination therapy of antidepressants and atypical antipsychotics (15.9%). Patients with ED-BP I disorder were more likely to be taking atypical antipsychotics than those with ED-BP II disorder, and were also more likely to be taking mood stabilizers and less likely to be taking antidepressants than those with ED-MDD. No differences presented in other comparisons between groups.

Discussion {#Sec19}
==========

Using structured interviews and self-administered questionnaires, we found that lifetime hypomania and mania were prevalent in ED patients with a current MDE, with bipolar I disorder being diagnosed in 17.2% and bipolar II in 24.2% of patients. There were varying associated psychopathology across groups with different comorbidities. ED-BP I and ED-BP II patients tended to have a greater body weight and increased suicidality, greater affect lability, impulsiveness, and a higher rate of alcohol use disorder than ED-MDD patients. Patients with ED-BP I reported the most severe binge-eating, depression, affect lability, impaired intelligence and working memory, and lifetime functional impairments. Although patients with ED-BP I had statistically significantly severe degrees of impulsiveness and higher co-occurrence rates of panic disorder and alcohol use disorder than patients with ED-MDD, they did not differ from patients with ED-BP II in these dimensions. Twenty-seven percent of ED-BP I patients were treated with antidepressant monotherapy that left this subgroup of patients unprotected from future mood switch and increased likelihood of chronicity of illness.

This study successfully illustrated heterogeneity among ED patients with a current MDE. Anxiety, impulsivity, suicide attempts, and alcohol/drug use disorders are prevailing comorbidities observed in ED patients \[[@CR5], [@CR52]--[@CR54]\]. Our study found that ED-BP I patients had a two-fold higher rate of comorbidity with panic disorder and ED-BP I and ED-BP II patients had a higher rate of comorbidity with alcohol use disorders (14- and 7-fold, respectively) compared to those with ED-MDD. This observation was consistent with prior findings that individuals with bipolar spectrum disorders had significantly higher rates of many psychiatric disorders, including panic disorder and alcohol use disorders \[[@CR31]\]. It is noteworthy that prior suicide attempts were reported by approximately 30% of our ED patients with bipolar I and bipolar II disorders and that the suicide risk was two-fold higher in this population compared to ED patients with comorbid MDD. These findings were in line with two earlier studies reporting that suicidal or self-destructive behavior in ED patients is associated with bipolar disorder \[[@CR55], [@CR56]\]. The presence of EDs has been implicated as a marker of clinical severity in patients with bipolar disorders, including more frequent suicide attempts than among those without EDs \[[@CR13], [@CR14], [@CR57]\]. The co-existence of EDs and bipolar disorders, especially bipolar I, indicates greater risks of suicide and psychiatric comorbidity in both groups of patients.

It is interesting to notice that heterogeneity also existed between patients with ED-BP I and ED-BP II when compared to those with ED-MDD. Patients with ED-BP II appeared to share affect and behavioral dysregulations with ED-BP I, but did not have as severe degrees of cognitive and functional impairments as ED-BP I. This finding added more evidence to support earlier concerns that failure to recognize the history or co-existence of hypomania symptoms in patients with MDE might result in no or correspondingly inadequate treatment as discussed as follows.

Although the benefits of antidepressant monotherapy remain unclear in the treatment of bipolar depression \[[@CR35]\], it is the most common initial prescription in all ED patients with a current MDE. Patients with ED-bipolar II had a comparable rate of being prescribed antidepressant monotherapy with patients with ED-MDD, and were more likely currently taking antidepressants monotherapy than patients with ED-bipolar I, leaving the concern that patients with hypomania might be less likely than those with mania to be identified from patients with MDEs or they had received adequate treatment for associated problems by taking antidepressants monotherapy. Antidepressant monotherapy may, however, expose ED patients with comorbid bipolar spectrum disorders to a potentially increased risk of mood lability and poor impulse control, among other dangerous consequences. There is a growing consensus from experts that antidepressant monotherapy should be avoided in patients with bipolar I disorder, patients with bipolar depression with two or more concomitant manic symptoms, and in bipolar patients with high mood instability or with a history of rapid cycling \[[@CR35], [@CR58]\]. Several researchers have addressed the role of affect lability or hypomania symptoms in binge-eating behaviors or other impulsive behaviors in ED patients \[[@CR12], [@CR59]\]. With comparison to the recognition of history of mania, hypomania, or mixed episodes, mood lability may be a more obvious indicator to avoid antidepressant monotherapy.

Several open series studies \[[@CR60]\] or double-blind placebo-controlled studies \[[@CR61]--[@CR63]\] have demonstrated that atypical antipsychotics, e.g. olanzapine and quetiapine, have efficacy in reducing depressive or obsessive symptoms and causing weight gain in patients with AN. However, studies examining the efficacy of atypical antipsychotics in reducing binge-eating in patients with BN are scarce. Use of atypical antipsychotics in the treatment of EDs was not uncommon among our patients (40.2% − 56.8%). Although meta-analysis studies have yielded disappointing result \[[@CR64]\], it is believed that some ED patients might benefit from antipsychotic medication \[[@CR33], [@CR65], [@CR66]\]. Mood stabilizers have not had a large role in the treatment of EDs and topiramate (an anticonvulsant) had well-established efficacy in reducing binge-eating frequency and weight loss \[[@CR67]\]. Both were not used frequently in our sample. Our results provide support for the rationale of the use of antipsychotics or mood stabilizers in the treatment of ED patients if comorbid bipolar disorders can be identified via the recognition of associated features reported in this present study. We hypothesize that treatment effects on affect lability and impulsivity might offset adverse effects of weight gain by taking antipsychotics or mood stabilizers and are beneficial for eating and weight control in a subgroup of ED patients with co-occurring bipolar disorders. However, further work to determine the indication and efficacy of atypical antipsychotics or mood stabilizers in the treatment of EDs is merited.

This study did have a few methodological limitations. The first was the small sample size. Consequently, all types of EDs were grouped together. Different ED subtypes may have different risks of association with psychiatric morbidities that would have influences on our current findings. Second, participants were selected in a tertiary center in a non-Western country, and thus, the sample may not be representative of the population with EDs elsewhere. Third, the medication use reported in this study was per psychiatrists' prescriptions from their initial encounters with patients. We did not follow up any changes in prescription at subsequent visits, or check patients' compliance in taking these medications. Finally, this is a cross-sectional design, and diagnosis of lifetime hypomania/mania was per patients' self-reports. Recall bias may exist. In spite of these limitations, to our knowledge, this is a pioneering work, examining the influence of bipolar disorders on ED patients during MDEs. It has important implications for pharmacotherapy in the management of ED.

Conclusions {#Sec20}
===========

Our study identified discriminative features of bipolar I and II disorders from MDD among a group of depressed ED patients. It is critical to recognize the presence of mood lability, a history of hypomanic/manic episodes, and other features associated with bipolar disorders, to evaluate if individuals with major depression may have hidden bipolarity. The co-occurrence of bipolar disorders in ED patients may provide clues indicating disease severity and the likelihood of presentation of impulsiveness, suicidality, psychiatric comorbidities, and even cognitive and functional impairments. The use of antidepressants in patients with EDs should be considered carefully if they have co-existent dysregulated mood and behavioral symptoms.
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